Role and Therapeutic Potential of E3s in the Tumor Microenvironment of Hepatocellular Carcinoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 15

PMID 39544935

Authors

Hailin Wang

Qiang Li

Qinqin Tang

Gang Shi

Guo Wu

Xingbo Mao

Changkang Wu

Lixin Zhang

Jie Liu

Jingdong Li

Bo Li

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a high-incidence, poor-prognosis malignancy worldwide, requiring new strategies for treatment. Ubiquitination, especially ubiquitination through E3 ubiquitin ligases, plays an indispensable role in the development and progression of HCC. E3 ubiquitin ligases are crucial enzymes in ubiquitination, controlling the degradation of specific substrate proteins and influencing various cellular functions, such as tumor cell proliferation, apoptosis, migration, and immune evasion. In this review, we systematically summarize the mechanisms of E3 ubiquitin ligases in HCC, with a focus on the significance of RING, HECT, and RBR types in HCC progression. The review also looks at the potential for targeting E3 ligases to modulate the tumor microenvironment (TME) and increase immunotherapy efficacy. Future studies will optimize HCC treatment by formulating specific inhibitors or approaches that will be based on gene therapy targeting E3 ligases in order to overcome resistance issues with present treatments and create optimism in the journey of treatment for HCC patients.

References

Befeler A, Di Bisceglie A . Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002; 122(6):1609-19. DOI: 10.1053/gast.2002.33411. View

Chen Y, Chang L . Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/Abl. Mol Nutr Food Res. 2012; 56(9):1398-412. DOI: 10.1002/mnfr.201200167. View

Hoeller D, Dikic I . Targeting the ubiquitin system in cancer therapy. Nature. 2009; 458(7237):438-44. DOI: 10.1038/nature07960. View

Huang C, Yang J, Chen J, Tai S, Yeh Y, Liu P . Fluoroquinolones Suppress TGF-β and PMA-Induced MMP-9 Production in Cancer Cells: Implications in Repurposing Quinolone Antibiotics for Cancer Treatment. Int J Mol Sci. 2021; 22(21). PMC: 8584204. DOI: 10.3390/ijms222111602. View

Xie L, Dai H, Li M, Yang W, Yu G, Wang X . MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways. J Cell Mol Med. 2019; 23(5):3386-3401. PMC: 6484336. DOI: 10.1111/jcmm.14235. View

Wei M, Mo Y, Liu J, Zhai J, Li H, Xu Y . Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. Front Oncol. 2022; 12:835603. PMC: 9374197. DOI: 10.3389/fonc.2022.835603. View

Zhang W, Zhang R, Zeng Y, Li Y, Chen Y, Zhou J . ALCAP2 inhibits lung adenocarcinoma cell proliferation, migration and invasion via the ubiquitination of β-catenin by upregulating the E3 ligase NEDD4L. Cell Death Dis. 2021; 12(8):755. PMC: 8324825. DOI: 10.1038/s41419-021-04043-6. View

Ren X, Wang L, Liu L, Liu J . PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy. Front Immunol. 2024; 15:1392546. PMC: 11024247. DOI: 10.3389/fimmu.2024.1392546. View

Deng L, Meng T, Chen L, Wei W, Wang P . The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020; 5(1):11. PMC: 7048745. DOI: 10.1038/s41392-020-0107-0. View

10.

Zhang J, Huang L, Ge G, Hu K . Emerging Epigenetic-Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment. Adv Sci (Weinh). 2023; 10(7):e2206169. PMC: 9982594. DOI: 10.1002/advs.202206169. View

11.

Rabellino A, Andreani C, Scaglioni P . The Role of PIAS SUMO E3-Ligases in Cancer. Cancer Res. 2017; 77(7):1542-1547. PMC: 5380518. DOI: 10.1158/0008-5472.CAN-16-2958. View

12.

Scheau C, Badarau I, Costache R, Caruntu C, Mihai G, Didilescu A . The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma. Anal Cell Pathol (Amst). 2019; 2019:9423907. PMC: 6899323. DOI: 10.1155/2019/9423907. View

13.

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

14.

Zeng Z, Gu S, Wong C, Yang L, Ouardaoui N, Li D . Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response. Sci Adv. 2022; 8(41):eabm8564. PMC: 9565795. DOI: 10.1126/sciadv.abm8564. View

15.

Guo F, Liu J, Han X, Zhang X, Lin T, Wang Y . Erratum: FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis. Int J Biol Sci. 2022; 18(3):1052. PMC: 8771842. DOI: 10.7150/ijbs.69330. View

16.

Zhang S, Jiang C, Jiang L, Chen H, Huang J, Gao X . Construction of a diagnostic model for hepatitis B-related hepatocellular carcinoma using machine learning and artificial neural networks and revealing the correlation by immunoassay. Tumour Virus Res. 2023; 16:200271. PMC: 10638043. DOI: 10.1016/j.tvr.2023.200271. View

17.

Xu S, Qin Y, Pan D, Ye G, Wu C, Wang S . Inhibition of WWP2 suppresses proliferation, and induces G1 cell cycle arrest and apoptosis in liver cancer cells. Mol Med Rep. 2016; 13(3):2261-6. DOI: 10.3892/mmr.2016.4771. View

18.

Chanmee T, Ontong P, Konno K, Itano N . Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014; 6(3):1670-90. PMC: 4190561. DOI: 10.3390/cancers6031670. View

19.

Frion-Herrera Y, Gabbia D, Cuesta-Rubio O, De Martin S, Carrara M . Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. Life Sci. 2019; 235:116817. DOI: 10.1016/j.lfs.2019.116817. View

20.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View